Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Xalatan (latanoprost) ophthalmic solution

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

March 2012

Summary View

ADVERSE REACTIONS

  • periorbital and lid changes resulting in deepening of the eyelid sulcus
     

August 2010

Summary View

ADVERSE REACTIONS

Clinical Practice
  • dizziness
  • headache
-
-